BioSpace News Archive

After a topsy-turvy 2023, thousands of industry stakeholders will attend next week’s J.P. Morgan Healthcare Conference in San Francisco to answer a fundamental question: What will this year look like?

Sensorion announces that the research partnership framework agreement signed in 2019 with the Institut Pasteur granting Sensorion an option for exclusive licenses to develop and market gene therapy drug candidates from collaborative projects to address unmet medical needs in the hearing field has been extended for a period of five years.

selectION, Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Bionomics Limited announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California.

Orion Corporation (“Orion”) and MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) have initiated two pivotal Phase 3 clinical trials evaluating ODM-208/MK5684, an investigational CYP11A1 inhibitor, in combination with hormone replacement therapy (HRT), for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.

Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.

EndoQuest™ Robotics, Inc. and OMNIVISION announced a partnership to integrate OMNIVISION’s OCHFA CameraCubeChip® into EndoQuest’s Flexible Robotic System.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 19,251 shares of its common stock to six new employees.